Low-Dose Tirzepatide Improves Metabolic Health in Psoriasis and Obesity, suggests study

A new study published in the journal of Dermatology and Therapy showed that treatment with low-dose tirzepatide was linked to clinically significant changes in important metabolic markers in individuals with psoriasis and obesity.

Type 2 diabetes and obesity can be effectively treated with tirzepatide, a new dual GIP and GLP-1 receptor agonist. It considerably improves body weight, insulin resistance, and general cardiometabolic health in addition to reducing blood sugar. Obesity and metabolic syndrome are closely associated with psoriasis, a chronic inflammatory skin disorder.

As a result, psoriasis patients have a greater cardiometabolic load and need treatments that address both metabolic dysregulation and skin inflammation at the same time. Despite the obvious theoretical advantages, there is still very little clinical data on tirzepatide's effectiveness in treating obesity and psoriasis in particular. Few research have looked at whether the medication's significant metabolic benefits also result in a decrease in the activity of psoriatic disease.

This study examines the effect of tirzepatide on obese psoriasis patients in an effort to close this gap. In particular, it assesses how the medication affects anthropometric measures, metabolic profiles, and its ability to enhance the management of psoriatic illness.

64 persons with obesity (body mass index [BMI] > 30 kg/m2) and chronic plaque psoriasis participated in this prospective observational research. Every patient was kept on stable ixekizumab treatment while receiving tirzepatide 2.5 mg with titration to 5 mg monthly. At baseline and week 24, anthropometric measurements, fasting glucose, lipid profiles, liver and renal function tests, and visceral adiposity indices were evaluated.

Significant decreases in body weight (−10%), BMI (−3.5 units), and waist-to-hip ratio (−8%) (p < 0.001) were noted at week 24. While low-density lipoprotein (LDL)-cholesterol (−6.7%, p < 0.001) and triglycerides (−15.4%, p = 0.003) considerably improved, fasting glucose dropped by 11.9% (p < 0.001).

Alanine transaminase (ALT) and aspartate aminotransferase (AST) both dropped by 11.6% and 12.4%, respectively. Renal function did not change. Scores on the Psoriasis Area and Severity Index (PASI) dropped from 4.2 ± 3.9 to 1.01 ± 0.9 (−76%, p < 0.001).

Overall, these results suggest that tirzepatide may be a useful treatment choice for all-encompassing metabolic control in individuals with obesity and psoriasis, supporting biologic therapy and treating systemic comorbidities. To clarify the molecular connections between metabolic improvement and psoriasis outcomes and to ascertain if tirzepatide may be involved in integrated therapy regimens for psoriatic illness, more controlled research is necessary.

Source:

Gisondi, P., & Girolomoni, G. (2026). Effects of tirzepatide on metabolic parameters in patients with psoriasis and obesity: 24-week real-world study. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01812-z